Scientific Update

This program will include a discussion of off-label treatments not approved by the FDA for use in the US.

Introduction and Recap

Nonpharmacologic Interventions

Treatment of Bipolar Depression

FDA-Approved Agents for Bipolar Disorder in Children and Adolescents

Impact of Age on Antidepressant-Related Adverse Effects in Youth at Risk for Bipolar Disorder

Antidepressants for Depression Associated With Bipolar Disorder in Youth

Negative Reactions to Antidepressants Among Youth With Bipolar Disorder

Children's Depression Rating Scale

Lithium for Youth With Depression Associated With Bipolar I Disorder: An Open-Label Study

Lamotrigine for Youth With Bipolar Spectrum Disorders: An Open-Label Study

Quetiapine in Youth With Depressive Episodes Associated With Bipolar I Disorder

Quetiapine XR in Youth With Acute Bipolar Depression

OFC for Youth Aged 10 to 17 Years With Bipolar Depression

A Double-Blind, Placebo-Controlled Trial of Lurasidone for Youth With Bipolar Depression

Study Demographics and Primary Outcome Measure: CDRS-R Total Score

Most Common AEs* and Trial Safety Summary

Results of 2-Year Open-Label Study: Efficacy and Safety

Roles of Clinicians and the Community When Managing Pediatric Bipolar Depression

Concluding Remarks

Abbreviations

Abbreviations (cont)